Tuberculosis - Pipeline Review, H2 2020
Tuberculosis - Pipeline Review, H2 2020
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Tuberculosis - Pipeline Review, H2 2020, provides an overview of the Tuberculosis (Infectious Disease) pipeline landscape.
Tuberculosis, commonly known as TB, is a bacterial infection that can spread through the lymph nodes and bloodstream to any organ in body. It is most often found in the lungs. The symptoms of tuberculosis range from no symptoms (latent tuberculosis) to symptoms of active disease. Symptoms include overall sensation of feeling unwell; cough, possibly with bloody mucus, fatigue, shortness of breath, weight loss and pain in the chest.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Tuberculosis - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Tuberculosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Tuberculosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Tuberculosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 6, 11, 8, 1, 63, 35 and 5 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 6, 8, 35 and 35 molecules, respectively.
Tuberculosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Tuberculosis - Pipeline Review, H2 2020, provides an overview of the Tuberculosis (Infectious Disease) pipeline landscape.
Tuberculosis, commonly known as TB, is a bacterial infection that can spread through the lymph nodes and bloodstream to any organ in body. It is most often found in the lungs. The symptoms of tuberculosis range from no symptoms (latent tuberculosis) to symptoms of active disease. Symptoms include overall sensation of feeling unwell; cough, possibly with bloody mucus, fatigue, shortness of breath, weight loss and pain in the chest.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Tuberculosis - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Tuberculosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Tuberculosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Tuberculosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 6, 11, 8, 1, 63, 35 and 5 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 6, 8, 35 and 35 molecules, respectively.
Tuberculosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Tuberculosis (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Tuberculosis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Tuberculosis (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Tuberculosis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Tuberculosis (Infectious Disease)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Tuberculosis (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Tuberculosis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Tuberculosis- Overview
Tuberculosis- Therapeutics Development
Tuberculosis- Therapeutics Assessment
Tuberculosis- Companies Involved in Therapeutics Development
Tuberculosis- Drug Profiles
Tuberculosis- Dormant Projects
Tuberculosis- Discontinued Products
Tuberculosis- Product Development Milestones
Appendix
Tuberculosis- Overview
Tuberculosis- Therapeutics Development
Tuberculosis- Therapeutics Assessment
Tuberculosis- Companies Involved in Therapeutics Development
Tuberculosis- Drug Profiles
Tuberculosis- Dormant Projects
Tuberculosis- Discontinued Products
Tuberculosis- Product Development Milestones
Appendix
LIST OF TABLES
Number of Products under Development for Tuberculosis, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Tuberculosis - Pipeline by Abera Bioscience AB, H2 2020
Tuberculosis - Pipeline by AGILeBiotics BV, H2 2020
Tuberculosis - Pipeline by Akshaya Bio Inc, H2 2020
Tuberculosis - Pipeline by Amgen Inc, H2 2020
Tuberculosis - Pipeline by AN2 Therapeutics Inc, H2 2020
Tuberculosis - Pipeline by Archivel Farma SL, H2 2020
Tuberculosis - Pipeline by AstraZeneca Plc, H2 2020
Tuberculosis - Pipeline by Austrianni GmbH, H2 2020
Tuberculosis - Pipeline by BioLingus AG, H2 2020
Tuberculosis - Pipeline by BioNTech SE, H2 2020
Tuberculosis - Pipeline by Bioversys AG, H2 2020
Tuberculosis - Pipeline by Bristol-Myers Squibb Co, H2 2020
Tuberculosis - Pipeline by C&O Pharmaceutical Technology (Holdings) Ltd, H2 2020
Tuberculosis - Pipeline by CanSino Biologics Inc, H2 2020
Tuberculosis - Pipeline by Catabasis Pharmaceuticals Inc, H2 2020
Tuberculosis - Pipeline by Chongqing Zhifei Biological Products Co Ltd, H2 2020
Tuberculosis - Pipeline by Collaborations Pharmaceuticals Inc, H2 2020
Tuberculosis - Pipeline by Consegna Pharma Inc, H2 2020
Tuberculosis - Pipeline by Crestone Inc, H2 2020
Tuberculosis - Pipeline by Daiichi Sankyo Co Ltd, H2 2020
Tuberculosis - Pipeline by Demuris Ltd, H2 2020
Tuberculosis - Pipeline by Eisai Co Ltd, H2 2020
Tuberculosis - Pipeline by Eli Lilly and Co, H2 2020
Tuberculosis - Pipeline by Ena Therapeutics Pty Ltd, H2 2020
Tuberculosis - Pipeline by Enyo Pharma SA, H2 2020
Tuberculosis - Pipeline by EpiVax Inc, H2 2020
Tuberculosis - Pipeline by Evotec SE, H2 2020
Tuberculosis - Pipeline by EyeGene Inc, H2 2020
Tuberculosis - Pipeline by Faron Pharmaceuticals Oy, H2 2020
Tuberculosis - Pipeline by Gamaleya Federal Research Center of Epidemiology and Microbiology, H2 2020
Tuberculosis - Pipeline by GC Pharma, H2 2020
Tuberculosis - Pipeline by GlaxoSmithKline Plc, H2 2020
Tuberculosis - Pipeline by Globeimmune Inc, H2 2020
Tuberculosis - Pipeline by Greffex Inc, H2 2020
Tuberculosis - Pipeline by Guangdong Zhongsheng Pharmaceutical Co Ltd, H2 2020
Tuberculosis - Pipeline by Guangzhou Egg Biotechnology Co Ltd, H2 2020
Tuberculosis - Pipeline by HanaVax Inc, H2 2020
Tuberculosis - Pipeline by Hsiri Therapeutics LLC, H2 2020
Tuberculosis - Pipeline by Immodulon Therapeutics Ltd, H2 2020
Tuberculosis - Pipeline by Immunitor Inc, H2 2020
Tuberculosis - Pipeline by ImmunoBiology Ltd, H2 2020
Tuberculosis - Pipeline by Innovare R & D SA De CV, H2 2020
Tuberculosis - Pipeline by Johnson & Johnson, H2 2020
Tuberculosis - Dormant Projects, H2 2020
Tuberculosis - Discontinued Products, H2 2020
Number of Products under Development for Tuberculosis, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Tuberculosis - Pipeline by Abera Bioscience AB, H2 2020
Tuberculosis - Pipeline by AGILeBiotics BV, H2 2020
Tuberculosis - Pipeline by Akshaya Bio Inc, H2 2020
Tuberculosis - Pipeline by Amgen Inc, H2 2020
Tuberculosis - Pipeline by AN2 Therapeutics Inc, H2 2020
Tuberculosis - Pipeline by Archivel Farma SL, H2 2020
Tuberculosis - Pipeline by AstraZeneca Plc, H2 2020
Tuberculosis - Pipeline by Austrianni GmbH, H2 2020
Tuberculosis - Pipeline by BioLingus AG, H2 2020
Tuberculosis - Pipeline by BioNTech SE, H2 2020
Tuberculosis - Pipeline by Bioversys AG, H2 2020
Tuberculosis - Pipeline by Bristol-Myers Squibb Co, H2 2020
Tuberculosis - Pipeline by C&O Pharmaceutical Technology (Holdings) Ltd, H2 2020
Tuberculosis - Pipeline by CanSino Biologics Inc, H2 2020
Tuberculosis - Pipeline by Catabasis Pharmaceuticals Inc, H2 2020
Tuberculosis - Pipeline by Chongqing Zhifei Biological Products Co Ltd, H2 2020
Tuberculosis - Pipeline by Collaborations Pharmaceuticals Inc, H2 2020
Tuberculosis - Pipeline by Consegna Pharma Inc, H2 2020
Tuberculosis - Pipeline by Crestone Inc, H2 2020
Tuberculosis - Pipeline by Daiichi Sankyo Co Ltd, H2 2020
Tuberculosis - Pipeline by Demuris Ltd, H2 2020
Tuberculosis - Pipeline by Eisai Co Ltd, H2 2020
Tuberculosis - Pipeline by Eli Lilly and Co, H2 2020
Tuberculosis - Pipeline by Ena Therapeutics Pty Ltd, H2 2020
Tuberculosis - Pipeline by Enyo Pharma SA, H2 2020
Tuberculosis - Pipeline by EpiVax Inc, H2 2020
Tuberculosis - Pipeline by Evotec SE, H2 2020
Tuberculosis - Pipeline by EyeGene Inc, H2 2020
Tuberculosis - Pipeline by Faron Pharmaceuticals Oy, H2 2020
Tuberculosis - Pipeline by Gamaleya Federal Research Center of Epidemiology and Microbiology, H2 2020
Tuberculosis - Pipeline by GC Pharma, H2 2020
Tuberculosis - Pipeline by GlaxoSmithKline Plc, H2 2020
Tuberculosis - Pipeline by Globeimmune Inc, H2 2020
Tuberculosis - Pipeline by Greffex Inc, H2 2020
Tuberculosis - Pipeline by Guangdong Zhongsheng Pharmaceutical Co Ltd, H2 2020
Tuberculosis - Pipeline by Guangzhou Egg Biotechnology Co Ltd, H2 2020
Tuberculosis - Pipeline by HanaVax Inc, H2 2020
Tuberculosis - Pipeline by Hsiri Therapeutics LLC, H2 2020
Tuberculosis - Pipeline by Immodulon Therapeutics Ltd, H2 2020
Tuberculosis - Pipeline by Immunitor Inc, H2 2020
Tuberculosis - Pipeline by ImmunoBiology Ltd, H2 2020
Tuberculosis - Pipeline by Innovare R & D SA De CV, H2 2020
Tuberculosis - Pipeline by Johnson & Johnson, H2 2020
Tuberculosis - Dormant Projects, H2 2020
Tuberculosis - Discontinued Products, H2 2020
LIST OF FIGURES
Number of Products under Development for Tuberculosis, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Top 10 Routes of Administration, H2 2020
Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020
Number of Products under Development for Tuberculosis, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Top 10 Routes of Administration, H2 2020
Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020
